Global Specimen Validity Testing
Global Specimen Validity Testing

Specimen Validity Testing Comprehensive Study by Type (Laboratory Testing, Rapid/POC Testing), Application (Workplaces, Drug Screening Laboratories, Criminal Justice and Law Enforcement Agencies, Pain Management Centers, Drug Rehabilitation Centers, Others), Function (Products, Services), Products (Reagent, Calibrators, and Controls, Assay Kits, Disposables) Players and Region - Global Market Outlook to 2025

Specimen Validity Testing Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 207 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Specimen Validity Testing Market?

Urine is the most generally utilized example for medications of misuse testing. This is essentially in light of the fact that pee is promptly accessible in huge amounts and contains high convergences of parent medications and metabolites. It is consequently, an acknowledged method of testing for example legitimacy when observing for mishandled drugs whether inside the working environment, criminal equity framework (for example drug courts) or for compliance.1 as a rule, human pee reflects drugs devoured inside the previous a few days relying upon drug use. Owing to all the benefits and ease in testing urine specimens, urine samples are extremely susceptible to tampering1, making it tempting for participants to either use adulterants or dilute their urine.

The market study is being classified by Type (Laboratory Testing and Rapid/POC Testing), by Application (Workplaces, Drug Screening Laboratories, Criminal Justice and Law Enforcement Agencies, Pain Management Centers, Drug Rehabilitation Centers and Others) and major geographies with country level break-up.

Thermo Fisher (United States), Sciteck. (United States), Alere (United States), Express Diagnostics (United States), Premier Biotech (United States), LabCorp (United States), Quest Diagnostics (United States), Alere Toxicology (United States), ACM Global Laboratories (United States), Clinical Reference Laboratory (CRL) (United States) and SureHire (Canada) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are CannAmm (Canada).

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Specimen Validity Testing market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Specimen Validity Testing market by Type, Application and Region.

On the basis of geography, the market of Specimen Validity Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growth in the Drug Screening and strict laws mandating drug screening and government funding to control drug abuse are projected to fuel the growth
  • Increase in Workplace Drug Testing

Market Trend
  • Regulatory Approvals for Rapid Testing Products

Restraints
  • Alternative Drug Screening Tests

Opportunities
  • Rise in health care infrastructure, and surge in funding from market players





Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Specimen Validity Testing Manufacturer, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Laboratory Testing
  • Rapid/POC Testing
By Application
  • Workplaces
  • Drug Screening Laboratories
  • Criminal Justice and Law Enforcement Agencies
  • Pain Management Centers
  • Drug Rehabilitation Centers
  • Others
By Function
  • Products
  • Services

By Products
  • Reagent, Calibrators, and Controls
  • Assay Kits
  • Disposables

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth in the Drug Screening and strict laws mandating drug screening and government funding to control drug abuse are projected to fuel the growth
      • 3.2.2. Increase in Workplace Drug Testing
    • 3.3. Market Trends
      • 3.3.1. Regulatory Approvals for Rapid Testing Products
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Specimen Validity Testing, by Type, Application, Function, Products and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Specimen Validity Testing (Value)
      • 5.2.1. Global Specimen Validity Testing by: Type (Value)
        • 5.2.1.1. Laboratory Testing
        • 5.2.1.2. Rapid/POC Testing
      • 5.2.2. Global Specimen Validity Testing by: Application (Value)
        • 5.2.2.1. Workplaces
        • 5.2.2.2. Drug Screening Laboratories
        • 5.2.2.3. Criminal Justice and Law Enforcement Agencies
        • 5.2.2.4. Pain Management Centers
        • 5.2.2.5. Drug Rehabilitation Centers
        • 5.2.2.6. Others
      • 5.2.3. Global Specimen Validity Testing by: Function (Value)
        • 5.2.3.1. Products
        • 5.2.3.2. Services
      • 5.2.4. Global Specimen Validity Testing by: Products (Value)
        • 5.2.4.1. Reagent, Calibrators, and Controls
        • 5.2.4.2. Assay Kits
        • 5.2.4.3. Disposables
      • 5.2.5. Global Specimen Validity Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Specimen Validity Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sciteck. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Alere (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Express Diagnostics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Premier Biotech (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LabCorp (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Quest Diagnostics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Alere Toxicology (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. ACM Global Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Clinical Reference Laboratory (CRL) (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. SureHire (Canada)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Specimen Validity Testing Sale, by Type, Application, Function, Products and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Specimen Validity Testing (Value)
      • 7.2.1. Global Specimen Validity Testing by: Type (Value)
        • 7.2.1.1. Laboratory Testing
        • 7.2.1.2. Rapid/POC Testing
      • 7.2.2. Global Specimen Validity Testing by: Application (Value)
        • 7.2.2.1. Workplaces
        • 7.2.2.2. Drug Screening Laboratories
        • 7.2.2.3. Criminal Justice and Law Enforcement Agencies
        • 7.2.2.4. Pain Management Centers
        • 7.2.2.5. Drug Rehabilitation Centers
        • 7.2.2.6. Others
      • 7.2.3. Global Specimen Validity Testing by: Function (Value)
        • 7.2.3.1. Products
        • 7.2.3.2. Services
      • 7.2.4. Global Specimen Validity Testing by: Products (Value)
        • 7.2.4.1. Reagent, Calibrators, and Controls
        • 7.2.4.2. Assay Kits
        • 7.2.4.3. Disposables
      • 7.2.5. Global Specimen Validity Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Specimen Validity Testing: by Type(USD Million)
  • Table 2. Specimen Validity Testing Laboratory Testing , by Region USD Million (2014-2019)
  • Table 3. Specimen Validity Testing Rapid/POC Testing , by Region USD Million (2014-2019)
  • Table 4. Specimen Validity Testing: by Application(USD Million)
  • Table 5. Specimen Validity Testing Workplaces , by Region USD Million (2014-2019)
  • Table 6. Specimen Validity Testing Drug Screening Laboratories , by Region USD Million (2014-2019)
  • Table 7. Specimen Validity Testing Criminal Justice and Law Enforcement Agencies , by Region USD Million (2014-2019)
  • Table 8. Specimen Validity Testing Pain Management Centers , by Region USD Million (2014-2019)
  • Table 9. Specimen Validity Testing Drug Rehabilitation Centers , by Region USD Million (2014-2019)
  • Table 10. Specimen Validity Testing Others , by Region USD Million (2014-2019)
  • Table 11. Specimen Validity Testing: by Function(USD Million)
  • Table 12. Specimen Validity Testing Products , by Region USD Million (2014-2019)
  • Table 13. Specimen Validity Testing Services , by Region USD Million (2014-2019)
  • Table 14. Specimen Validity Testing: by Products(USD Million)
  • Table 15. Specimen Validity Testing Reagent, Calibrators, and Controls , by Region USD Million (2014-2019)
  • Table 16. Specimen Validity Testing Assay Kits , by Region USD Million (2014-2019)
  • Table 17. Specimen Validity Testing Disposables , by Region USD Million (2014-2019)
  • Table 18. South America Specimen Validity Testing, by Country USD Million (2014-2019)
  • Table 19. South America Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 20. South America Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 21. South America Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 22. South America Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 23. Brazil Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 24. Brazil Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 25. Brazil Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 26. Brazil Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 27. Argentina Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 28. Argentina Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 29. Argentina Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 30. Argentina Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 31. Rest of South America Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 32. Rest of South America Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 33. Rest of South America Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 34. Rest of South America Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 35. Asia Pacific Specimen Validity Testing, by Country USD Million (2014-2019)
  • Table 36. Asia Pacific Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 37. Asia Pacific Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 38. Asia Pacific Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 39. Asia Pacific Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 40. China Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 41. China Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 42. China Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 43. China Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 44. Japan Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 45. Japan Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 46. Japan Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 47. Japan Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 48. India Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 49. India Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 50. India Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 51. India Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 52. South Korea Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 53. South Korea Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 54. South Korea Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 55. South Korea Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 56. Taiwan Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 57. Taiwan Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 58. Taiwan Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 59. Taiwan Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 60. Australia Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 61. Australia Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 62. Australia Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 63. Australia Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 68. Europe Specimen Validity Testing, by Country USD Million (2014-2019)
  • Table 69. Europe Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 70. Europe Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 71. Europe Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 72. Europe Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 73. Germany Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 74. Germany Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 75. Germany Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 76. Germany Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 77. France Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 78. France Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 79. France Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 80. France Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 81. Italy Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 82. Italy Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 83. Italy Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 84. Italy Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 85. United Kingdom Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 86. United Kingdom Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 87. United Kingdom Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 88. United Kingdom Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 89. Netherlands Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 90. Netherlands Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 91. Netherlands Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 92. Netherlands Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 93. Rest of Europe Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 94. Rest of Europe Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 95. Rest of Europe Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 96. Rest of Europe Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 97. MEA Specimen Validity Testing, by Country USD Million (2014-2019)
  • Table 98. MEA Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 99. MEA Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 100. MEA Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 101. MEA Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 102. Middle East Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 103. Middle East Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 104. Middle East Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 105. Middle East Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 106. Africa Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 107. Africa Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 108. Africa Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 109. Africa Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 110. North America Specimen Validity Testing, by Country USD Million (2014-2019)
  • Table 111. North America Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 112. North America Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 113. North America Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 114. North America Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 115. United States Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 116. United States Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 117. United States Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 118. United States Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 119. Canada Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 120. Canada Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 121. Canada Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 122. Canada Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 123. Mexico Specimen Validity Testing, by Type USD Million (2014-2019)
  • Table 124. Mexico Specimen Validity Testing, by Application USD Million (2014-2019)
  • Table 125. Mexico Specimen Validity Testing, by Function USD Million (2014-2019)
  • Table 126. Mexico Specimen Validity Testing, by Products USD Million (2014-2019)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Specimen Validity Testing: by Type(USD Million)
  • Table 139. Specimen Validity Testing Laboratory Testing , by Region USD Million (2020-2025)
  • Table 140. Specimen Validity Testing Rapid/POC Testing , by Region USD Million (2020-2025)
  • Table 141. Specimen Validity Testing: by Application(USD Million)
  • Table 142. Specimen Validity Testing Workplaces , by Region USD Million (2020-2025)
  • Table 143. Specimen Validity Testing Drug Screening Laboratories , by Region USD Million (2020-2025)
  • Table 144. Specimen Validity Testing Criminal Justice and Law Enforcement Agencies , by Region USD Million (2020-2025)
  • Table 145. Specimen Validity Testing Pain Management Centers , by Region USD Million (2020-2025)
  • Table 146. Specimen Validity Testing Drug Rehabilitation Centers , by Region USD Million (2020-2025)
  • Table 147. Specimen Validity Testing Others , by Region USD Million (2020-2025)
  • Table 148. Specimen Validity Testing: by Function(USD Million)
  • Table 149. Specimen Validity Testing Products , by Region USD Million (2020-2025)
  • Table 150. Specimen Validity Testing Services , by Region USD Million (2020-2025)
  • Table 151. Specimen Validity Testing: by Products(USD Million)
  • Table 152. Specimen Validity Testing Reagent, Calibrators, and Controls , by Region USD Million (2020-2025)
  • Table 153. Specimen Validity Testing Assay Kits , by Region USD Million (2020-2025)
  • Table 154. Specimen Validity Testing Disposables , by Region USD Million (2020-2025)
  • Table 155. South America Specimen Validity Testing, by Country USD Million (2020-2025)
  • Table 156. South America Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 157. South America Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 158. South America Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 159. South America Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 160. Brazil Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 161. Brazil Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 162. Brazil Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 163. Brazil Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 164. Argentina Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 165. Argentina Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 166. Argentina Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 167. Argentina Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 168. Rest of South America Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 169. Rest of South America Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 170. Rest of South America Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 171. Rest of South America Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 172. Asia Pacific Specimen Validity Testing, by Country USD Million (2020-2025)
  • Table 173. Asia Pacific Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 174. Asia Pacific Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 175. Asia Pacific Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 176. Asia Pacific Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 177. China Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 178. China Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 179. China Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 180. China Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 181. Japan Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 182. Japan Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 183. Japan Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 184. Japan Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 185. India Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 186. India Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 187. India Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 188. India Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 189. South Korea Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 190. South Korea Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 191. South Korea Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 192. South Korea Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 193. Taiwan Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 194. Taiwan Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 195. Taiwan Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 196. Taiwan Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 197. Australia Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 198. Australia Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 199. Australia Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 200. Australia Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 201. Rest of Asia-Pacific Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 202. Rest of Asia-Pacific Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 203. Rest of Asia-Pacific Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 204. Rest of Asia-Pacific Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 205. Europe Specimen Validity Testing, by Country USD Million (2020-2025)
  • Table 206. Europe Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 207. Europe Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 208. Europe Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 209. Europe Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 210. Germany Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 211. Germany Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 212. Germany Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 213. Germany Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 214. France Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 215. France Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 216. France Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 217. France Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 218. Italy Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 219. Italy Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 220. Italy Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 221. Italy Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 222. United Kingdom Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 223. United Kingdom Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 224. United Kingdom Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 225. United Kingdom Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 226. Netherlands Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 227. Netherlands Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 228. Netherlands Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 229. Netherlands Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 230. Rest of Europe Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 231. Rest of Europe Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 232. Rest of Europe Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 233. Rest of Europe Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 234. MEA Specimen Validity Testing, by Country USD Million (2020-2025)
  • Table 235. MEA Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 236. MEA Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 237. MEA Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 238. MEA Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 239. Middle East Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 240. Middle East Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 241. Middle East Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 242. Middle East Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 243. Africa Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 244. Africa Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 245. Africa Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 246. Africa Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 247. North America Specimen Validity Testing, by Country USD Million (2020-2025)
  • Table 248. North America Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 249. North America Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 250. North America Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 251. North America Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 252. United States Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 253. United States Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 254. United States Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 255. United States Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 256. Canada Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 257. Canada Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 258. Canada Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 259. Canada Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 260. Mexico Specimen Validity Testing, by Type USD Million (2020-2025)
  • Table 261. Mexico Specimen Validity Testing, by Application USD Million (2020-2025)
  • Table 262. Mexico Specimen Validity Testing, by Function USD Million (2020-2025)
  • Table 263. Mexico Specimen Validity Testing, by Products USD Million (2020-2025)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Specimen Validity Testing: by Type USD Million (2014-2019)
  • Figure 5. Global Specimen Validity Testing: by Application USD Million (2014-2019)
  • Figure 6. Global Specimen Validity Testing: by Function USD Million (2014-2019)
  • Figure 7. Global Specimen Validity Testing: by Products USD Million (2014-2019)
  • Figure 8. South America Specimen Validity Testing Share (%), by Country
  • Figure 9. Asia Pacific Specimen Validity Testing Share (%), by Country
  • Figure 10. Europe Specimen Validity Testing Share (%), by Country
  • Figure 11. MEA Specimen Validity Testing Share (%), by Country
  • Figure 12. North America Specimen Validity Testing Share (%), by Country
  • Figure 13. Global Specimen Validity Testing share by Players 2019 (%)
  • Figure 14. Global Specimen Validity Testing share by Players (Top 3) 2019(%)
  • Figure 15. Global Specimen Validity Testing share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Thermo Fisher (United States) Revenue, Net Income and Gross profit
  • Figure 18. Thermo Fisher (United States) Revenue: by Geography 2019
  • Figure 19. Sciteck. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Sciteck. (United States) Revenue: by Geography 2019
  • Figure 21. Alere (United States) Revenue, Net Income and Gross profit
  • Figure 22. Alere (United States) Revenue: by Geography 2019
  • Figure 23. Express Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 24. Express Diagnostics (United States) Revenue: by Geography 2019
  • Figure 25. Premier Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 26. Premier Biotech (United States) Revenue: by Geography 2019
  • Figure 27. LabCorp (United States) Revenue, Net Income and Gross profit
  • Figure 28. LabCorp (United States) Revenue: by Geography 2019
  • Figure 29. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 30. Quest Diagnostics (United States) Revenue: by Geography 2019
  • Figure 31. Alere Toxicology (United States) Revenue, Net Income and Gross profit
  • Figure 32. Alere Toxicology (United States) Revenue: by Geography 2019
  • Figure 33. ACM Global Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 34. ACM Global Laboratories (United States) Revenue: by Geography 2019
  • Figure 35. Clinical Reference Laboratory (CRL) (United States) Revenue, Net Income and Gross profit
  • Figure 36. Clinical Reference Laboratory (CRL) (United States) Revenue: by Geography 2019
  • Figure 37. SureHire (Canada) Revenue, Net Income and Gross profit
  • Figure 38. SureHire (Canada) Revenue: by Geography 2019
  • Figure 39. Global Specimen Validity Testing: by Type USD Million (2020-2025)
  • Figure 40. Global Specimen Validity Testing: by Application USD Million (2020-2025)
  • Figure 41. Global Specimen Validity Testing: by Function USD Million (2020-2025)
  • Figure 42. Global Specimen Validity Testing: by Products USD Million (2020-2025)
  • Figure 43. South America Specimen Validity Testing Share (%), by Country
  • Figure 44. Asia Pacific Specimen Validity Testing Share (%), by Country
  • Figure 45. Europe Specimen Validity Testing Share (%), by Country
  • Figure 46. MEA Specimen Validity Testing Share (%), by Country
  • Figure 47. North America Specimen Validity Testing Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Thermo Fisher (United States)
  • Sciteck. (United States)
  • Alere (United States)
  • Express Diagnostics (United States)
  • Premier Biotech (United States)
  • LabCorp (United States)
  • Quest Diagnostics (United States)
  • Alere Toxicology (United States)
  • ACM Global Laboratories (United States)
  • Clinical Reference Laboratory (CRL) (United States)
  • SureHire (Canada)
Additional players considered in the study are as follows:
CannAmm (Canada)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation